Black Diamond Therapeutics, Inc. (BDTX) stock
Close on Nov 11, 2026Market cap $92.50MP/E –Yield –
Black Diamond Therapeutics, Inc. saw revenue fall 100.0% to $0 over the twelve months to Sep 30, 2026. Operating income fell 547.4% to -$53.05M. At the latest close the market valued the company at $92.50M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $92.50M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.05
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $0
- Net income
- -$44.07M
- EPS, diluted
- -$0.76
- Book value per share
- $1.53
- Diluted shares
- 57M
Trading
- Next earnings
- Mar 15, 2027 (estimated, during market hours)
- Previous close
- $1.59
- Open
- $1.68
- Day's range
- $1.58 – $1.69
- Volume
- 852,499
- Average volume (20 days)
- 884,686
- Index membership
- Russell 2000 (since Jun 2026)
- Beta (5 years)
- 2.49
- 52-week range
- $1.58 – $4.94
- RSI (14 days)
- 41.7
- Volatility (1 year)
- 83.0%
- Relative volume
- 1.19×
- WACC
- 17.3%
On 1 of our idea list: More cash than they're worth
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | BDTX | S&P 500 | Difference | BDTX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -12.0% | -2.4% | −9.6 pts | ||
| 3 months | -23.0% | -1.2% | −21.8 pts | ||
| Year to date | -33.7% | +12.3% | −46.0 pts | ||
| 1 year | -65.2% | +12.4% | −77.6 pts | ||
| 3 years | -9.6% | +78.8% | −88.4 pts | -3.3% | +21.4% |
| 5 years | -79.7% | +75.2% | −154.9 pts | -27.3% | +11.9% |
Nine years at a glance
Fiscal years 2017 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Black Diamond Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Results
- Results
- Results
About Black Diamond Therapeutics
Biological Products, (No Diagnostic Substances)
Black Diamond Therapeutics is a clinical-stage oncology company that discovers and develops orally available, small molecule therapies for patients with genetically defined cancers. Using its proprietary MAP drug discovery platform, the company designs brain-penetrant MasterKey inhibitors that target shared oncogenic mutation families across multiple tumor types while minimizing toxicities. Its lead clinical product candidate is silevertinib, an irreversible EGFR MasterKey inhibitor evaluated in clinical trials for non-small cell lung cancer and glioblastoma. The company also developed BDTX-4933, a brain-penetrant RAF inhibitor whose worldwide development and commercialization rights are licensed to Servier, and is pursuing partnerships for its preclinical FGFR2/3 development program, BDTX-4876.
Company profile, executives and historyBlack Diamond Therapeutics stock: common questions
What is Black Diamond Therapeutics's stock price?
BDTX closed at $1.61 on Nov 11, 2026, up 0.94% on the day. Over the past 52 weeks it traded between $1.58 and $4.94.
What is Black Diamond Therapeutics's market cap?
Black Diamond Therapeutics was worth $92.50M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is BDTX's P/E ratio?
Black Diamond Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.76), so it has no meaningful P/E ratio.
How much revenue does Black Diamond Therapeutics make?
Black Diamond Therapeutics reported revenue of $0 for the twelve months to Sep 30, 2026, down 100.0% from a year earlier.
Does Black Diamond Therapeutics pay a dividend?
No. Black Diamond Therapeutics has not paid a cash dividend over the last twelve months.
When does Black Diamond Therapeutics report earnings next?
Black Diamond Therapeutics is expected to report Q4 FY2026 results on Mar 15, 2027, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has BDTX stock performed over the past year?
Including dividends, BDTX returned -65.2% over the past year, against +12.4% for the S&P 500.
How many BDTX shares are sold short?
5M shares were sold short at the latest FINRA report, 9.78% of the float, or 4.9 days of average trading volume.
Who are Black Diamond Therapeutics's competitors?
Companies most similar to Black Diamond Therapeutics by business, industry and size include KYMR, STRO, CHRS, CCCC, GLUE.
See a number that looks wrong?